Bank of America
ENTA icon

Bank of America’s Enanta Pharmaceuticals ENTA Stock Holding History

Bank of America’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$336K Sell
26,593
-39,385
-60% -$528K ﹤0.01% 5096
2025
Q4 		$1.04M Buy
65,978
+36,026
+120% +$458K ﹤0.01% 4504
2025
Q3 		$359K Sell
29,952
-27,059
-47% -$216K ﹤0.01% 5980
2025
Q2 		$431K Sell
57,011
-14,916
-21% -$89.7K ﹤0.01% 5789
2025
Q1 		$397K Buy
71,927
+63,905
+797% +$395K ﹤0.01% 5782
2024
Q4 		$46.1K Sell
8,022
-701,630
-99% -$6.73M ﹤0.01% 6652
2024
Q3 		$7.35M Buy
709,652
+113,739
+19% +$1.49M ﹤0.01% 3377
2024
Q2 		$7.73M Buy
595,913
+79,547
+15% +$1.07M ﹤0.01% 3201
2024
Q1 		$9.02M Buy
516,366
+504,106
+4,112% +$6.67M ﹤0.01% 3077
2023
Q4 		$115K Buy
12,260
+1,643
+15% +$15.3K ﹤0.01% 6320
2023
Q3 		$119K Sell
10,617
-45,105
-81% -$726K ﹤0.01% 6179
2023
Q2 		$1.19M Sell
55,722
-166,986
-75% -$4.92M ﹤0.01% 4639
2023
Q1 		$9.01M Buy
222,708
+167,431
+303% +$8M ﹤0.01% 2933
2022
Q4 		$2.57M Buy
55,277
+11,370
+26% +$518K ﹤0.01% 4028
2022
Q3 		$2.28M Buy
43,907
+31,273
+248% +$1.83M ﹤0.01% 4151
2022
Q2 		$597K Sell
12,634
-25,114
-67% -$1.36M ﹤0.01% 5296
2022
Q1 		$2.69M Buy
37,748
+19,154
+103% +$1.25M ﹤0.01% 4286
2021
Q4 		$1.39M Buy
18,594
+10,273
+123% +$806K ﹤0.01% 4931
2021
Q3 		$472K Buy
8,321
+1,104
+15% +$54.6K ﹤0.01% 5689
2021
Q2 		$317K Sell
7,217
-691
-9% -$33.8K ﹤0.01% 5764
2021
Q1 		$391K Buy
7,908
+462
+6% +$23K ﹤0.01% 5563
2020
Q4 		$314K Sell
7,446
-1,217
-14% -$53.5K ﹤0.01% 5308
2020
Q3 		$397K Sell
8,663
-3,167
-27% -$153K ﹤0.01% 4888
2020
Q2 		$595K Sell
11,830
-18,954
-62% -$981K ﹤0.01% 4485
2020
Q1 		$1.58M Buy
30,784
+20,471
+198% +$1.09M ﹤0.01% 3661
2019
Q4 		$637K Sell
10,313
-1,383
-12% -$85.7K ﹤0.01% 4835
2019
Q3 		$704K Sell
11,696
-30,089
-72% -$2.24M ﹤0.01% 4818
2019
Q2 		$3.52M Buy
41,785
+12,483
+43% +$1.12M ﹤0.01% 3557
2019
Q1 		$2.8M Buy
29,302
+21,426
+272% +$1.92M ﹤0.01% 3705
2018
Q4 		$558K Buy
7,876
+369
+5% +$28.3K ﹤0.01% 4860
2018
Q3 		$642K Sell
7,507
-5,361
-42% -$537K ﹤0.01% 4782
2018
Q2 		$1.49M Sell
12,868
-7,155
-36% -$714K ﹤0.01% 4198
2018
Q1 		$1.62M Buy
20,023
+4,078
+26% +$314K ﹤0.01% 4042
2017
Q4 		$935K Sell
15,945
-5,576
-26% -$279K ﹤0.01% 4532
2017
Q3 		$1.01M Buy
21,521
+703
+3% +$28.3K ﹤0.01% 4498
2017
Q2 		$749K Sell
20,818
-32,656
-61% -$1.04M ﹤0.01% 4625
2017
Q1 		$1.65M Buy
53,474
+34,429
+181% +$1.07M ﹤0.01% 4033
2016
Q4 		$638K Buy
19,045
+13,039
+217% +$374K ﹤0.01% 4647
2016
Q3 		$159K Sell
6,006
-208,079
-97% -$4.83M ﹤0.01% 5236
2016
Q2 		$4.72M Sell
214,085
-112,947
-35% -$2.96M ﹤0.01% 2840
2016
Q1 		$9.61M Buy
327,032
+28,672
+10% +$798K ﹤0.01% 2177
2015
Q4 		$9.85M Sell
298,360
-24,498
-8% -$798K ﹤0.01% 2266
2015
Q3 		$11.7M Buy
322,858
+303,667
+1,582% +$13M ﹤0.01% 2079
2015
Q2 		$863K Buy
19,191
+13,125
+216% +$511K ﹤0.01% 4226
2015
Q1 		$186K Sell
6,066
-1,135
-16% -$44.2K ﹤0.01% 4969
2014
Q4 		$367K Sell
7,201
-479
-6% -$21.4K ﹤0.01% 4884
2014
Q3 		$304K Buy
7,680
+7,581
+7,658% +$302K ﹤0.01% 5021
2014
Q2 		$4K Sell
99
-569
-85% -$21.7K ﹤0.01% 7704
2014
Q1 		$27K Sell
668
-2,267
-77% -$82.3K ﹤0.01% 6756
2013
Q4 		$80K Buy
2,935
+2,909
+11,188% +$70.5K ﹤0.01% 6279
2013
Q3 		$1K Sell
26
-4,849
-99% -$92.7K ﹤0.01% 7731
2013
Q2 		$86K Buy
+4,875
New +$95.1K ﹤0.01% 6233

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America's ENTA Position: Q1 2026 in Review

Bank of America reduced its Enanta Pharmaceuticals (ENTA) stake by 60% in Q1 2026, selling an estimated $528K and leaving 26,593 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #5096.

Bank of America first reported a position in ENTA in Q2 2013 and has held it in 52 quarters since. The position peaked at $11.7M in Q3 2015. 133 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • Bank of America held 26,593 shares of Enanta Pharmaceuticals worth $336K as of Q1 2026.
  • Bank of America sold 39,385 Enanta Pharmaceuticals shares in Q1 2026, an estimated $528K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5096 holding.
  • Bank of America first reported a position in Enanta Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Enanta Pharmaceuticals position peaked at $11.7M in Q3 2015.
  • 133 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.